Blood Cancer Discov. 2025 Apr 27:OF1-OF5. doi: 10.1158/2643-3230.BCD-25-0036. Online ahead of print.
ABSTRACT
Despite the remarkable efficacy of targeted therapies and immunotherapies in B-cell acute lymphoblastic leukemia (B-ALL), relapsed and refractory cases remain a major challenge. In this review, we discuss how integrating targeted agents with immunotherapy could help overcome resistance and improve long-term patient outcomes in B-ALL.
PMID:40287957 | DOI:10.1158/2643-3230.BCD-25-0036
